Simcere Pharmaceutical Group Limited provided consolidated earnings guidance for the year ended December 31, 2023. The group will record a revenue of approximately RMB 6,578 million to RMB 6,638 million for the year ended December 31, 2023, representing an increase of approximately 4.0% to 5.0% as compared to the restated revenue of approximately RMB 6,324 million for the year ended December 31, 2022. The Group will record a profit attributable to equity shareholders of the company of approximately RMB 685 million to RMB 745 million for fiscal year 2023, representing a decrease of approximately 20.0% to 26.4% as compared to the restated profit attributable to equity shareholders of the company of approximately RMB 931 million for fiscal year 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.72 HKD | +0.18% | +0.35% | -15.01% |
04-25 | Simcere Pharmaceutical’ Profit Down 23% in 2023 | MT |
04-10 | Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-15.01% | 1.87B | |
+20.43% | 43.57B | |
+20.70% | 22.7B | |
+15.26% | 14.32B | |
+11.77% | 13.42B | |
+45.10% | 11.83B | |
-8.84% | 6.98B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+12.33% | 5.51B |
- Stock Market
- Equities
- 2096 Stock
- News Simcere Pharmaceutical Group Limited
- Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023